Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

78.27 -0.73 (-0.92%)

Streaming Delayed Price Updated: 9:32 AM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >

What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally ↗

January 11, 2026

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally ↗

January 07, 2026

This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development.

Via The Motley Fool

Topics Regulatory Compliance

Why Apogee Therapeutics Stock Triumphed on Thursday ↗

October 09, 2025

The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.

Via The Motley Fool

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today ↗

October 09, 2025

Via Stocktwits

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out ↗

October 09, 2025

The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.

Via Investor's Business Daily

Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 09, 2025

Via Benzinga

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 08, 2025

Via Benzinga

What's going on in today's after hours session ↗

October 08, 2025

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Gold Falls 1%; ProKidney Shares Spike Higher ↗

July 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Dow Dips 1%; Mustang Bio Shares Spike Higher ↗

July 07, 2025

Via Benzinga

Topics Stocks

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

July 07, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot ↗

July 07, 2025

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.

Via Investor's Business Daily

What's going on in today's pre-market session ↗

July 07, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Top 2 Health Care Stocks That May Plunge This Month ↗

July 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 07, 2025

Via Benzinga

Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial ↗

July 07, 2025

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing.

Via Benzinga

Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket ↗

July 07, 2025

Via Benzinga

Why Is Apogee Therapeutics Stock Trading Higher On Monday? ↗

May 12, 2025

Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 20, 2025

Via Benzinga

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗

March 03, 2025

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.

Via Benzinga

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗

February 12, 2025

Via Benzinga

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

November 25, 2024

Via Benzinga

APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024 ↗

August 12, 2024

APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗

July 14, 2024

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Via Benzinga

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗

July 11, 2024

Via Benzinga

APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 ↗

May 13, 2024

APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Earnings Superstars: 3 Stocks Primed to Outperform This Quarter ↗

May 08, 2024

Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors.

Via InvestorPlace

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗

March 14, 2024

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.